Koichiro Komai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koichiro Komai has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Koji Inoue
Shichikawa Arthritis Research Center, Osaka Rehabilitation Hospital, Hannan, Japan
2 shared publicationsShunichi Shiozawa
Institute for Rheumatic Diseases, Ashiya, Japan
2 shared publications- Aiko Sunami
Department of Medical Laboratory Medicine, Faculty of Health Sciences, Kobe Tokiwa University, Kobe 653-0838, Japan
1 shared publication Akira Miyauchi
Department of Surgery, Kuma Hospital, Kobe, Japan
1 shared publication- Akira Nakayama
Department of Chemical System Engineering Graduate School of Engineering The University of Tokyo Tokyo Japan
1 shared publication Aoi Kishida
Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10110
The Need for Variant-Specific Splicing Assessment in Developing Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy: Lessons from the DMD c.4675−2A>G Variant
Duchenne muscular dystrophy is caused by pathogenic variants in the DMD gene. Splice-site variants can generate aberrant transcripts whose consequences cannot always be predicted by the classical reading-frame rule. Here, we characterized the c.4675−2A>G variant at the exon 34 splice acceptor site for the development of an exon-skipping therapy. A minigene analysis demonstrated that c.4675−2A>G activated a cryptic splice acceptor within exon 34 rather than inducing skipping of the entire exon, resulting in deletion of the first 7 nucleotides, a frameshift, and a premature termination codon. To restore the reading frame by promoting skipping of the entire exon 34, we used antisense oligonucleotides (ASOs) targeting distinct splice-regulatory regions. Among the ASO treatments tested, including individual ASOs and ASO combinations, A1&E4&D1 produced the highest exon exclusion and consistently promoted exon 34 skipping across the examined −2A mutant genotypes. A1&E4&D1 consists of ASOs A1, E4, and D1. A1 targeted the cryptic 3′ splice acceptor region, E4 targeted a predicted exonic splicing enhancer region, and D1 targeted the 5′ splice donor region. These findings illustrate a stepwise, variant-directed strategy in which characterization of aberrant splicing guides the design of a tailor-made ASO intervention.
- 11 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10110
Open AccessThe Need for Variant-Specific Splicing Assessment in Developing Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy: Lessons from the DMD c.4675−2A>G Variant
Duchenne muscular dystrophy is caused by pathogenic variants in the DMD gene. Splice-site variants can generate aberrant transcripts whose consequences cannot always be predicted by the classical reading-frame rule. Here, we characterized the c.4675−2A>G variant at the exon 34 splice acceptor site for the development of an exon-skipping therapy. A minigene analysis demonstrated that c.4675−2A>G activated a cryptic splice acceptor within exon 34 rather than inducing skipping of the entire exon, resulting in deletion of the first 7 nucleotides, a frameshift, and a premature termination codon. To restore the reading frame by promoting skipping of the entire exon 34, we used antisense oligonucleotides (ASOs) targeting distinct splice-regulatory regions. Among the ASO treatments tested, including individual ASOs and ASO combinations, A1&E4&D1 produced the highest exon exclusion and consistently promoted exon 34 skipping across the examined −2A mutant genotypes. A1&E4&D1 consists of ASOs A1, E4, and D1. A1 targeted the cryptic 3′ splice acceptor region, E4 targeted a predicted exonic splicing enhancer region, and D1 targeted the 5′ splice donor region. These findings illustrate a stepwise, variant-directed strategy in which characterization of aberrant splicing guides the design of a tailor-made ASO intervention.
- 30 April 2024
- Vol. 70 (1) , E26-E38
Genetic Rare Variants Affecting Multiple Pathways in Japanese Patients with Palindromic Rheumatism.
Palindromic rheumatism (PR) is a type of cryptogenic paroxysmal arthritis. Several genes may be involved in PR pathogenesis; however, conducting comprehensive case-control genetic studies for PR poses challenges owing to its rarity as a disease. Moreover, case-control studies may overlook rare variants that occur infrequently but play a significant role in pathogenesis. This study aimed to identify disease-related genes in Japanese patients with PR using whole-genome sequencing (WGS) and rare-variant analysis. Genomic DNA was obtained from two familial cases and one sporadic case, and it was subjected to WGS. WGS data of 104 healthy individuals obtained from a public database were used as controls. We performed data analysis for rare variants on detected variants using SKAT-O, KBAC, and SKAT, and subsequently defined significant genes. Significant genes combined with variants shared between the cases were defined as disease-related genes. We also performed pathway analysis for disease-related genes using Reactome. We identified 2,695,244 variants shared between cases; after excluding polymorphisms and noise, 74,640 variants were detected. We identified 540 disease-related genes, including 1,893 variants. Furthermore, we identified 32 significant pathways. Our results indicate that the detected genes and pathways in this study may be involved in PR pathogenesis.
- 30 April 2024
- Vol. 70 (1) , E26-E38
Genetic Rare Variants Affecting Multiple Pathways in Japanese Patients with Palindromic Rheumatism.
Palindromic rheumatism (PR) is a type of cryptogenic paroxysmal arthritis. Several genes may be involved in PR pathogenesis; however, conducting comprehensive case-control genetic studies for PR poses challenges owing to its rarity as a disease. Moreover, case-control studies may overlook rare variants that occur infrequently but play a significant role in pathogenesis. This study aimed to identify disease-related genes in Japanese patients with PR using whole-genome sequencing (WGS) and rare-variant analysis. Genomic DNA was obtained from two familial cases and one sporadic case, and it was subjected to WGS. WGS data of 104 healthy individuals obtained from a public database were used as controls. We performed data analysis for rare variants on detected variants using SKAT-O, KBAC, and SKAT, and subsequently defined significant genes. Significant genes combined with variants shared between the cases were defined as disease-related genes. We also performed pathway analysis for disease-related genes using Reactome. We identified 2,695,244 variants shared between cases; after excluding polymorphisms and noise, 74,640 variants were detected. We identified 540 disease-related genes, including 1,893 variants. Furthermore, we identified 32 significant pathways. Our results indicate that the detected genes and pathways in this study may be involved in PR pathogenesis.
- 25 April 2019
- Vol. 65 (1) , E1-E9
CD44v8-10 and CD44s Are Age-dependently Expressed in Primary Cultured Papillary Thyroid Carcinoma Cells and Are Associated with Cell Proliferation.
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, arising from follicular cells, and accounts for more than 80% of all thyroid malignant tumors. Although age is the strongest prognostic factor of PTC, and various cut-off ages (40-55 years) were suggested in previous studies, the molecular mechanisms causing age-related changes of PTC cell proliferation remain unclear. CD44 is a major cell surface receptor for hyaluronate and is known as a cancer stem cell marker. However, the association between CD44 and PTC is still unknown. Therefore, we determined the proliferation of primary cultured cells obtained from patients with PTC, and the CD44 mRNA expression profile to elucidate age-related association of CD44 with PTC. The results showed that cell proliferation was significantly decreased according to age. We also found that CD44v8-10 and CD44 splice variants were expressed dominantly in patients with PTC. Moreover, the CD44v8-10/CD44s mRNA expression ratio was significantly increased according to age, and there was a significant negative correlation between this expression ratio and cell proliferation. Our findings suggest that the CD44v8-10/CD44s expression ratio in PTC cells is useful for screening for aggressive PTC and may provide clinically valuable information.
- 25 April 2019
- Vol. 65 (1) , E1-E9
CD44v8-10 and CD44s Are Age-dependently Expressed in Primary Cultured Papillary Thyroid Carcinoma Cells and Are Associated with Cell Proliferation.
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, arising from follicular cells, and accounts for more than 80% of all thyroid malignant tumors. Although age is the strongest prognostic factor of PTC, and various cut-off ages (40-55 years) were suggested in previous studies, the molecular mechanisms causing age-related changes of PTC cell proliferation remain unclear. CD44 is a major cell surface receptor for hyaluronate and is known as a cancer stem cell marker. However, the association between CD44 and PTC is still unknown. Therefore, we determined the proliferation of primary cultured cells obtained from patients with PTC, and the CD44 mRNA expression profile to elucidate age-related association of CD44 with PTC. The results showed that cell proliferation was significantly decreased according to age. We also found that CD44v8-10 and CD44 splice variants were expressed dominantly in patients with PTC. Moreover, the CD44v8-10/CD44s mRNA expression ratio was significantly increased according to age, and there was a significant negative correlation between this expression ratio and cell proliferation. Our findings suggest that the CD44v8-10/CD44s expression ratio in PTC cells is useful for screening for aggressive PTC and may provide clinically valuable information.
- 1 January 2019
- Published by Allergy, Asthma, and Immunology Association of Thailand in Asian Pacific Journal of Allergy and Immunology
- Vol. 40 (1) , 81-86
Expression of a PYCARD/ASC variant lacking exon 2 in Japanese patients with palindromic rheumatism increases interleukin-1β secretion
Background: Palindromic rheumatism (PR) is a rare periodic arthritis characterized by relapsing short episodes of arthritis. Although the pathogenesis of PR is still unclear, the clinical condition is similar to that of autoinflammatory diseases caused by dysregulation of inflammasome-related genes. Objective: We analyzed the inflammasome adapter PYD and CARD domain-containing protein/apoptosis-associated speck-like protein containing a CARD (PYCARD/ASC) in Japanese patients with PR. Methods: Serum interleukin (IL)-1 beta concentrations in three Japanese patients with PR were measured. We also cloned PYCARD/ASC cDNA variants and expressed them in THP-1 cells to determine their effects on inflammasome activity following stimulation with phorbol 12-myristate 13-acetate and monosodium urate. Lysates of recombinant THP-1 cells were subjected to co-immunoprecipitation assays. Results: Serum IL-1 beta concentrations were significantly elevated in patients with PR, and a splice variant of PYCARD/ASC mRNA lacking exon 2 (Delta exon2) was dominantly expressed compared with that in controls. Moreover, IL-1 beta secretion was significantly increased in THP-1 cells expressing Delta exon2 PYCARD/ASC compared with that in cells expressing the wild-type protein. The amount of NLRP3 bound to Delta exon2 PYCARD/ASC was increased after stimulation, whereas that bound to the wild-type protein was decreased. There were no differences in caspase-1 binding. Conclusion: Delta exon2 PYCARD/ASC was associated with the pathogenesis of PR.
- 1 January 2019
- Published by Allergy, Asthma, and Immunology Association of Thailand in Asian Pacific Journal of Allergy and Immunology
- Vol. 40 (1) , 81-86
Expression of a PYCARD/ASC variant lacking exon 2 in Japanese patients with palindromic rheumatism increases interleukin-1β secretion
Background: Palindromic rheumatism (PR) is a rare periodic arthritis characterized by relapsing short episodes of arthritis. Although the pathogenesis of PR is still unclear, the clinical condition is similar to that of autoinflammatory diseases caused by dysregulation of inflammasome-related genes. Objective: We analyzed the inflammasome adapter PYD and CARD domain-containing protein/apoptosis-associated speck-like protein containing a CARD (PYCARD/ASC) in Japanese patients with PR. Methods: Serum interleukin (IL)-1 beta concentrations in three Japanese patients with PR were measured. We also cloned PYCARD/ASC cDNA variants and expressed them in THP-1 cells to determine their effects on inflammasome activity following stimulation with phorbol 12-myristate 13-acetate and monosodium urate. Lysates of recombinant THP-1 cells were subjected to co-immunoprecipitation assays. Results: Serum IL-1 beta concentrations were significantly elevated in patients with PR, and a splice variant of PYCARD/ASC mRNA lacking exon 2 (Delta exon2) was dominantly expressed compared with that in controls. Moreover, IL-1 beta secretion was significantly increased in THP-1 cells expressing Delta exon2 PYCARD/ASC compared with that in cells expressing the wild-type protein. The amount of NLRP3 bound to Delta exon2 PYCARD/ASC was increased after stimulation, whereas that bound to the wild-type protein was decreased. There were no differences in caspase-1 binding. Conclusion: Delta exon2 PYCARD/ASC was associated with the pathogenesis of PR.
- Open Access
- 1 January 2004
- Published by Pesticide Science Society of Japan in Journal of Pesticide Science
- Vol. 29 (4) , 413-418
CONTENTS OF VOLUME 29, 2004
- 1 January 2004
- Published by Pesticide Science Society of Japan in Journal of Pesticide Science
- Vol. 29 (4) , 413-418
Open AccessCONTENTS OF VOLUME 29, 2004